INTRODUCTION
============

Symptomatic hip dysplasia may lead to pain and reduced hip function \[[@hnz009-B1], [@hnz009-B2]\]; if untreated, it is a known risk factor to secondary osteoarthritis \[[@hnz009-B1], [@hnz009-B3]\]. The causes of hip dysplasia are believed to be multifactorial and known common risk factors are familiar disposition and female gender \[[@hnz009-B4], [@hnz009-B5]\]. In Denmark, the estimated prevalence of hip dysplasia is ∼3.4%, but not all patients will experience symptoms \[[@hnz009-B6], [@hnz009-B7]\]. The typical patient with hip dysplasia experiences symptoms from the age of 20--40 years and has an average activity level before onset of symptoms \[[@hnz009-B2], [@hnz009-B8]\]. Hip dysplasia can be treated surgically with periacetabular osteotomy (PAO) to increase acetabular coverage of the femoral head and decrease pressure on the hip joint \[[@hnz009-B9]\]. The clinical aim of PAO is to reduce pain, to maintain or improve the patient's function and quality of life (QoL) and furthermore to prevent or delay the development of osteoarthritis \[[@hnz009-B3], [@hnz009-B10]\]. Several studies have reported positive changes in hip function after PAO \[[@hnz009-B3], [@hnz009-B11]\] and the majority of physically active patients return to the preoperative or higher activity level \[[@hnz009-B15]\]. PAO may improve pain \[[@hnz009-B12], [@hnz009-B14], [@hnz009-B16]\] and QoL \[[@hnz009-B12], [@hnz009-B17]\], but no previous studies have examined associations between changes in pain and changes in QoL and hip function after PAO. Thus, the aim of this study was to investigate whether changes in pain were associated with changes in QoL and hip function 2 years after PAO. Furthermore, to examine patient satisfaction 2 years after PAO.

MATERIALS AND METHODS
=====================

Study design and setting
------------------------

This study is a follow-up study and data were collected from a local database at Department of Orthopaedic Surgery at Aarhus University Hospital (AUH). The database contains information about 1771 patients undergoing reverse PAO, femoral osteotomy and PAO using the minimally invasive transsartorial approach and operated by co-authors K.S. or S.S.J.

Study population and selection
------------------------------

The study population consists of patients diagnosed with hip dysplasia operated with the minimally invasive transsartorial PAO approach at AUH and the Private Hospital Mølholm in the period between 1 January 2012 and 1 April 2016. Indications for PAO were centre-edge angle \<25°, persistent hip pain, reduced walking distance, hip congruence, Tönnis osteoarthritis Grade 0--1, hip flexion \>110° and internal hip rotation \>15°.

Patients were included if they: (i) had hip dysplasia, (ii) underwent PAO with the minimally invasive transsartorial approach at AUH or at the Private Hospital Mølholm and (iii) had completed the preoperative questionnaire. Patients were excluded if they: (i) had not fully completed the Visual Analogue Scale (VAS), Hip disability and Osteoarthritis Outcome Score (HOOS) and Short-Form-36 (SF-36) in the preoperative questionnaire or at follow-up after 2 years, (ii) underwent PAO due to other diagnoses than hip dysplasia, (iii) underwent reverse PAO or femoral osteotomy and finally, (iv) in patients operated bilaterally, the second operated hip was excluded. Data from the preoperative questionnaire are included in the database from the year 2012, and thus data from patients operated from this year onwards were included in the study. A total of 629 patients completed the pre-operative questionnaire between 1 January 2012 and 1 April 2016. Among the 629 patients, 158 were excluded. In the remaining 471 patients, 121 were lost to follow-up and 29 patients were excluded due to not fully completing the questionnaire at follow-up. Thus, 321 patients were included in the study ([Fig. 1](#hnz009-F1){ref-type="fig"}).

![Flowchart showing inclusion and exclusion of patients. PAO, periacetabular osteotomy; VAS, Visual Analogue Scale; HOOS, Hip Disability and Osteoarthritis Outcome Score; SF-36, short-Form 36.](hnz009f1){#hnz009-F1}

Data collection
---------------

Patients were invited to a pre-operative information meeting and encouraged to complete the preoperative questionnaire online or on paper. Information on demographics, VAS, SF-36 and HOOS was extracted for this study. At 2-year follow-up, the questionnaire was sent to the patients online or by mail. A reminder was sent to the patients if they did not respond within a month. A second reminder was sent if patients did still not answer. After this, patients were not contacted any further. Information on VAS, SF-36, HOOS and patient satisfaction was extracted at 2-year follow-up. On the day of surgery, the surgeon completed a questionnaire with information about the operation, diagnosis, clinical tests and other patient relevant information. Data were extracted from this questionnaire on diagnosis, right/left hip and type of operation.

Changes in pain
---------------

Information on hip pain at rest was self-reported using the VAS. The VAS is a validated, reliable and clinically relevant tool to measure pain \[[@hnz009-B18]\]. A score of 100 indicates 'the worst possible pain' \[[@hnz009-B18], [@hnz009-B19]\].

Changes in QoL
--------------

Changes in QoL were self-reported using the questionnaire SF-36 completed at baseline and at 2-year follow-up. The SF-36 is a validated and reliable measure of health-related mental and physical QoL \[[@hnz009-B20]\] and consists of 36 questions within eight health domains. From the eight health domains are two health components calculated: physical component summary score (PCS) and mental component summary score (MCS) \[[@hnz009-B21]\], which are used as outcome measures in this study. All health domains contribute to the two health components, but in varying degrees \[[@hnz009-B24]\]. The score in the two health components range from 0 to 100; 100 indicates best possible health status \[[@hnz009-B23]\].

Changes in hip function
-----------------------

Changes in hip function were self-reported using the questionnaire HOOS completed at baseline and at 2-year follow-up. The HOOS is used for patients with reduced hip function with or without hip osteoarthritis \[[@hnz009-B25]\]. The HOOS consists of five subscales: HOOS pain, HOOS symptoms, HOOS activities of daily living (ADL), HOOS sport/recreation and HOOS QoL. A HOOS score is calculated for each subscale ranging from 0 to 100; 0 indicates an extreme degree of symptoms and 100 indicate no symptoms \[[@hnz009-B25]\]. The HOOS is valid and reliable in patients with osteoarthritis and patients undergoing hip arthroscopic surgery. Furthermore, it was found sensitive to measure changes over time \[[@hnz009-B26], [@hnz009-B27]\]. The subscales HOOS ADL, HOOS sport/recreation and HOOS symptom were used.

Confounding
-----------

Potential confounders for the association between changes in pain and the two primary outcomes, changes in QoL and changes in hip function, were identified through a systematic literature search and clinical reasoning. The following variables were identified: gender \[[@hnz009-B12]\], age \[[@hnz009-B10], [@hnz009-B12], [@hnz009-B16]\], body mass index (BMI) \[[@hnz009-B12]\], pre-operative hip function \[[@hnz009-B11], [@hnz009-B28]\], pre-operative QoL and unilateral/bilateral surgery throughout the study period.

Patient satisfaction
--------------------

At 2-year follow-up, patients indicated level of satisfaction responding to the following three questions: When you think of your daily life, your pain, your symptoms, disability and QoL, do you see your current situation as satisfying?On a scale from 0 to 10, where 10 is the best, how satisfied are you overall with the progress and result of your hip surgery so far?If you had known your progress and result of the surgery before you were operated, would you then still undergo surgery?

Statistical analysis
--------------------

All analyses were performed in STATA 15 (StataCorp LP, College Station, TX, USA) and all hypotheses were tested using a 5% significance level. Demographics were described. Mean changes in pain; QoL and hip function were tested for statistical significance using the paired *t*-test. Analyses of mean changes were performed in such a way that positive estimates indicated improvement. A check for floor and ceiling effect was performed on all five HOOS subscales and was considered present if more than 15% achieved the lowest or highest possible score.

The primary aim of the study was investigated through multiple linear regressions including adjustment for potential confounding. Crude and adjusted β-coefficients were estimated for all possible outcomes. Change in pain was considered the independent continuous variable. Change in QoL and change in hip function, respectively were considered dependent continuous variables. Model assumptions for multiple linear regressions with check for linear associations, normal distribution of residuals, constant variance of residuals and assumption of independent observations were performed through QQ-plots, scatter plots and dot plots.

A drop-out analysis was performed to investigate whether patients who did not complete the 2-year follow-up questionnaire differed significantly from patients who completed.

RESULTS
=======

Baseline characteristics
------------------------

Baseline characteristics of the 321 patients are presented in [Table I](#hnz009-T1){ref-type="table"}.

###### 

Baseline characteristics of the 321 included patients

  ----------------------------- -----------------------
  Variable, *n* = 321           
  Age, median (IQR)             31 years (22--39)
  Range                         14--49 years
  Gender, *n* (%)               283 females (88.16%)
  38 men (11.84%)               
  BMI, median (IQR) *n* = 319   23 kg/m^2^ (21--25)
  Range                         16--34
  Side of operation, *n* (%)    173 right (53.89%)
  148 left (46.11%)             
  Unilateral surgery, *n* (%)   274 patients (85.36%)
  Bilateral surgery, *n* (%)    47 patients (14.64%)
  VAS                           
   Median (IQR)                 34 (17--55)
   Range                        0--98
  SF-36, mean (SD)              
   PCS score                    35.68 (8.27)
   MCS                          50.39 (11.73)
  HOOS, mean (SD)               
   Pain                         53.15 (17.84)
   Symptoms                     51.54 (19.97)
   ADL                          63.55 (19.80)
   Sport/recreation             42.76 (22.92)
   QoL                          33.35 (16.21)
  ----------------------------- -----------------------

IQR, interquartile range; *n*, number; SD, standard deviation; BMI, body mass index; VAS, Visual Analogue Scale; SF-36, Short-Form 36; HOOS, Hip Disability and Osteoarthritis Outcome Score; ADL, activities of daily living; QoL, quality of life.

A ceiling effect was present for the subscales HOOS ADL (15.89%) and HOOS sport/recreation (15.26%) at 2-year follow-up.

Changes in pain, QoL and hip function 2 years after PAO
-------------------------------------------------------

Pain improved significantly between baseline and 2-year follow-up with a mean on 23.96 (95%CI: 21.09; 26.83). The SF-36 component scores and HOOS subscales all improved significantly from baseline to 2-year follow-up ([Table II](#hnz009-T2){ref-type="table"}).

###### 

Mean changes from baseline to 2-year follow-up for primary outcomes for QoL and hip function

  Outcomes (*n* = 321)                      Baseline, mean (SD)   Two-year follow-up, mean (SD)   Mean changes (follow-up -- baseline), mean (95%CI)   P-value[^a^](#tblfn3){ref-type="table-fn"}
  ----------------------------------------- --------------------- ------------------------------- ---------------------------------------------------- --------------------------------------------
  SF-36 Psychical component summary score   35.68 (8.27)          44.93 (10.38)                   9.26 (8.10; 10.42)                                   0.000
  SF-36 MCS                                 50.39 (11.73)         54.26 (9.93)                    3.87 (2.54; 5.20)                                    0.000
  HOOS pain                                 53.15 (17.84)         77.65 (19.78)                   24.50 (22.03; 26.97)                                 0.000
  HOOS symptoms                             51.54 (19.97)         71.37 (21.62)                   19.83 (17.18; 22.48)                                 0.000
  HOOS ADL                                  63.55 (19.80)         83.62 (18.34)                   20.08 (17.83; 22.33)                                 0.000
  HOOS sport/recreation                     42.76 (22.92)         69.49 (25.48)                   26.73 (23.63; 29.83)                                 0.000
  HOOS QoL                                  33.35 (16.21)         58.93 (24.75)                   25.58 (22.83; 28.32)                                 0.000

*n*, number; SD, standard deviation; SF-36, Short-Form 36; HOOS, Hip Disability and Osteoarthritis Outcome Score; ADL, activities of daily living; QoL, quality of life.

Paired *t*-test.

At 2-year follow-up the SF-36 scores were almost similar to the Danish background population \[[@hnz009-B21]\], especially in the primary mental health domains (Role-Emotional, Mental Health, Social Functioning, Vitality), whereas the scores for the physical health domains showed improvements, but did not reach the level of the Danish background population ([Fig. 2](#hnz009-F2){ref-type="fig"}).

![Mean scores for QoL within the eight health domains in SF-36 at baseline, 2-year follow-up and for the Danish background population \[[@hnz009-B21]\].](hnz009f2){#hnz009-F2}

Associations
------------

In the adjusted linear regression analyses, linear associations between changes in pain and changes in QoL measured with SF-36 PCS and changes in hip function measured with HOOS symptoms, HOOS ADL and HOOS sport/recreation were statistically significant ([Table III](#hnz009-T3){ref-type="table"}). The linear association between changes in pain and changes in QoL measured with SF-36 MCS were not statistically significant ([Table III](#hnz009-T3){ref-type="table"}).

###### 

Unadjusted and adjusted estimates for β--coefficients from the linear regression analysis for the associations between changes in pain measured with VAS and changes in QoL and changes in hip function measured with SF-36 and HOOS from baseline to 2-year follow-up

                            Unadjusted β-coefficients (95%CI), *n* = 321   P-value   Adj. *R*^2^   Adjusted β-coefficients (95%CI), *n* = 319   P-value   Adj. *R*^2^
  ------------------------- ---------------------------------------------- --------- ------------- -------------------------------------------- --------- -------------
  Δ SF-36 PCS               β = 0.17 (0.12; 0.21)                          0.000     0.16          β = 0.14 (0.09; 0.18)                        0.000     0.24
  Δ SF-36 MCS               β = 0.09 (0.04; 0.14)                          0.001     0.03          β = 0.04 (−0.01; 0.10)                       0.125     0.06
  Δ HOOS symptoms           β = 0.49 (0.40; 0.58)                          0.000     0.28          β = 0.44 (0.35; 0.53)                        0.000     0.34
  Δ HOOS ADL                β = 0.46 (0.39; 0.53)                          0.000     0.34          β = 0.37 (0.30; 0.44)                        0.000     0.43
  Δ HOOS sport/recreation   β = 0.47 (0.36; 0.58)                          0.000     0.19          β = 0.43 (0.32; 0.55)                        0.000     0.21

Adjusted for gender, baseline age, baseline BMI, unilateral/bilateral surgery, baseline SF-36 and baseline HOOS. In the adjusted analyses, no adjustments were made for the SF-36 or HOOS baseline score, which are in the same subscale as the outcome. *n*, number; Δ, change; Adj., adjusted; VAS, Visual Analogue Scale; SF-36, Short-Form 36; PCS, physical component summary score; MCS, mental component summary score; HOOS, Hip Disability and Osteoarthritis Outcome Score; ADL, activities of daily living.

A statistically significant positive dose-response association between changes in pain and changes in QoL measured with SF-36 PCS was estimated, where changes in QoL improved significantly with 0.14 (95%CI: 0.09; 0.18) per one point increase in changes in pain measured with VAS ([Table III](#hnz009-T3){ref-type="table"}). Changes in pain may together with potential confounders in the adjusted analysis explain 24% (*R*^2^ = 0.24) of the variation in changes in QoL measured with SF-36 PCS. Likewise, changes in pain may together with potential confounders explain 34% (*R*^2^ = 0.34) of the variation in the changes in hip function measured with HOOS symptoms, 43% (*R*^2^ = 0.43) of the variation in changes in hip function measured with HOOS ADL and 21% (*R*^2^ = 0.21) of the variation in changes in hip function measured with HOOS sport/recreation. Changes in pain may together with potential confounders explain 6% (*R*^2^ = 0.06) of the variation in changes in QoL measured with SF-36 MCS, though not statistically significant.

Patient satisfaction
--------------------

A total of 206 patients (64.17%) out of 321 patients indicated that their current situation in relation to daily life, pain, symptoms, disability and QoL was satisfactory. A total of 320 patients completed the questions about overall satisfaction with progress and result of the surgery with a median value of 8 (IQR: 8--9); 270 patients (84.11%) out of 321 patients indicated that they would undergo surgery again if they had known their progress and result in advance.

Drop-out analysis
-----------------

A total of 121 patients of the 471 patients diagnosed with hip dysplasia and undergoing PAO, did not complete the follow-up questionnaire, resulting in a loss to follow-up of 25.69%. A significantly higher proportion of men were lost to follow-up ([Table IV](#hnz009-T4){ref-type="table"}).

###### 

Drop-out analysis with baseline characteristics for patients lost to follow-up compared with participating patients

                      Patients lost to follow-up (*n* = 121)   Participating patients (n = 321)                      P-value
  ------------------- ---------------------------------------- ----------------------------------------------------- ------------------------------------------------
  Age, median (IQR)   27 years (21--37)                        31 years (22--39)                                     *P* = 0.193[^a^](#tblfn6){ref-type="table-fn"}
  Range               14--48 years                             14--49 years                                          
  Gender, *n* (%)     96 females (79.34%)                      283 females (88.16%)                                  *P* = 0.018[^b^](#tblfn6){ref-type="table-fn"}
  25 men (20.66%)     38 men (11.84%)                                                                                
  BMI, median (IQR)   23 kg/m^2^ (21--26)                      23 kg/m^2^ (21--25)                                   *P* = 0.113[^a^](#tblfn6){ref-type="table-fn"}
  Range               15--34                                   16--34 *n* = 319[^c^](#tblfn6){ref-type="table-fn"}   
  VAS, median (IQR)   33 (17--58)                              34 (17--55)                                           *P* = 0.684[^a^](#tblfn6){ref-type="table-fn"}
  Range               0--91                                    0--98                                                 
  SF-36, mean (SD)                                                                                                   
   PCS                36.39 (9, 51)                            35.68 (8, 27)                                         *P* = 0.439[^c^](#tblfn6){ref-type="table-fn"}
   MCS                49.45 (10, 78)                           50.39 (11, 73)                                        *P* = 0.441[^c^](#tblfn6){ref-type="table-fn"}
  HOOS, mean (SD)                                                                                                    
   Pain               55.17 (20.91)                            53.15 (17.84)                                         *P* = 0.348[^c^](#tblfn6){ref-type="table-fn"}
   Symptoms           55.70 (19.25)                            51.54 (19.97)                                         *P* = 0.050[^c^](#tblfn6){ref-type="table-fn"}
   ADL                64.60 (21.26)                            63.55 (19.80)                                         *P* = 0.627[^c^](#tblfn6){ref-type="table-fn"}
   Sport/recreation   44.78 (25.11)                            42.76 (22.92)                                         *P* = 0.420[^c^](#tblfn6){ref-type="table-fn"}
   QoL                34.48 (18.06)                            33.35 (16.21)                                         *P* = 0.528[^c^](#tblfn6){ref-type="table-fn"}

IQR, interquartile range; *n*, number; SD, standard deviation; BMI, body mass index; VAS, Visual Analogue Scale; SF-36, Short-Form 36; HOOS, Hip Disability and Osteoarthritis Outcome Score; ADL, activities of daily living;

Wilcoxon Rank Sum Test; ^b^*X*^2^ test; ^c^Unpaired *t*-test.

DISCUSSION
==========

This study showed positive statistically significant associations between changes in pain and changes in QoL and changes in hip function, respectively measured with SF-36 PCS, HOOS symptoms, HOOS ADL and HOOS sport/recreation 2 years after PAO. The study showed a statistically non-significant association between changes in pain and changes in QoL measured with SF-36 MCS 2 years after PAO.

To our knowledge, no previous studies have investigated the association between changes in pain and changes in QoL after PAO. A few studies have addressed mean changes in QoL after PAO \[[@hnz009-B12], [@hnz009-B17]\]. Van Bergayk *et al*. \[[@hnz009-B17]\] in a prospective follow-up study reported a significant improvement in QoL measured with SF-36 PCS 2 years after PAO; this is in line with the results of this study. In the study by Van Bergayk *et al*. \[[@hnz009-B17]\], no significant improvement on SF-36 MCS 2 years after PAO was found. This is in contrast to the results of this study where a significant improvement was found 2 years after PAO. The conflicting results may be due to differences in sample size as the study of Van Bergayk *et al*. possibly has too low statistical power to show significant changes.

A big multicentre study by Clohisy *et al*. \[[@hnz009-B12]\] demonstrated significant improvements in QoL measured with SF-12 PCS and MCS, which are comparable to the results of this study. Furthermore, this study demonstrated that the study population achieved QoL scores at 2-year follow-up close to scores for the Danish background population. This indicates that the mean changes in QoL in this study are clinically relevant for the patients.

Several studies report improvements in hip function and pain after PAO \[[@hnz009-B3], [@hnz009-B12], [@hnz009-B15], [@hnz009-B16]\]. In a systematic review from 2009, Clohisy *et al*. \[[@hnz009-B3]\] described improvement in hip function after PAO among patients with hip dysplasia in all included studies. Furthermore, the clinical outcome analysis demonstrated improvement in pain among the majority of patients with short to midterm follow-up \[[@hnz009-B3]\]. This supports the results of this study where significant improvements in pain and hip function 2 years after PAO were seen.

Bogunovic *et al*. \[[@hnz009-B15]\] also found significant improvements in all five HOOS subscales with a mean follow-up time of 33 months. Bogunovic *et al*. \[[@hnz009-B15]\] did not investigate the association between changes in pain and changes in hip function, but described that for 89% of the patients, reduction in pain was the primary cause of improvement in patient activities. This is not directly comparable to the primary result of this study, but parallels can be drawn to the fact that this study found positive associations between changes in pain and changes in hip function measured with three HOOS subscales.

Clohisy *et al*. \[[@hnz009-B12]\] found significant and clinically relevant improvements in all five HOOS subscales and presented minimal clinically important differences on HOOS symptoms of 9, HOOS pain of 9, HOOS ADL of 6, HOOS sport/recreation of 10 and HOOS QoL of 11. The findings by Clohisy et al. support the results of this study, and demonstrate that the mean changes for all five HOOS subscales in this study are clinically relevant changes.

This study showed that patients were generally satisfied with the result of PAO at 2-year follow-up, which is also reported in other studies \[[@hnz009-B12], [@hnz009-B15]\].

Internal validity
-----------------

The large sample size, the statistical analysis with adjustment for potential confounders and PAO being performed by only two surgeons are considered strengths of this study. The study used valid, reliable and patient relevant outcome measures, though not validated for the specific study population. Concerning limitations, this study has a high drop-out rate of 25.69%. This should be kept in mind when interpreting the results, since it is unknown whether participation of patients lost to follow-up would have affected the associations in other directions. A significantly higher proportion of men were lost to follow-up, which may affect the generalising of the results in male populations.

The differences in adjusted and unadjusted analyses varied for the different outcomes. The adjustment for confounding especially influenced the results for the association between changes in pain and changes in QoL measured with SF-36 MCS, where the association went from significant to non-significant. In the specific analysis, baseline SF-36 PCS was significantly associated with changes in QoL measured with SF-36 MCS; thus, baseline SF-36 PCS may be considered a significant confounder for the association.

External validity
-----------------

The results of this study may cautiously be generalised to patients with hip dysplasia undergoing PAO using the minimally invasive transsartorial approach under the same circumstances as described in this study. However, the internal validity should be considered, especially the large drop-out rate and the higher proportion of men dropping out.

CONCLUSION
==========

This study demonstrated that changes in pain were associated with changes in physically related QoL and changes in hip function, respectively 2 years after PAO. Higher improvements in pain are associated with higher improvements in physically related QoL and hip function. No significant association between changes in pain and changes in mentally related QoL was demonstrated. Patients indicated an overall satisfaction with post-surgical progress and results 2 years after PAO.
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